MSI2 and neoplasm: As depletion of MSI2 in human NSCLC cell lines reduced its invasion and metastatic potential [17], we suggest that MSI2 small molecule drugs in NSCLC may have a dual effect, i.e., not only by targeting and weakening tumor cells but also inactivating CAFs in the TME, thereby enhancing their effectiveness in NSCLC treatment.